Glinski to Oversee US Sales for XTANDI

-First Investigational Therapy in a Pivotal Trial to Address Unmet Need for Patients with Advanced Urothelial Cancer After Treatment with Platinum Chemotherapy and a PD-1 or PD-L1 Inhibitor-

- Phase 3 ADMIRAL trial showed patients treated with XOSPATA demonstrated longer Overall Survival than those who received salvage chemotherapy[1] -

-Total Funds To Be Awarded Increased to $200,000; All Encouraged to Apply -

- Data Presented at the American Urological Association 2019 Annual Meeting -

- Study results will be presented at American Association for Cancer Research Annual Meeting 2019 -